Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma
| Autor: | Jean-Baptiste Pialat, Lamia Bouazza, Marie Brevet, Michaël Duruisseaux, O Borel, Jean-Michel Maury, R Guelminger, M. Millet, Philippe Clézardin, Jean-Charles Rousseau, Lauriane Chambard, C Roger, Cyrille B. Confavreux, E Massy, Edith Bonnelye, Evelyne Gineyts, M. Gueye, Nicolas Girard |
|---|---|
| Přispěvatelé: | BONNELYE, Edith, Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases (LYOS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université Claude Bernard Lyon 1 - Faculté des sciences et technologies (UCBL FST), Université de Lyon-Université de Lyon, Hôpital Louis Pradel [CHU - HCL], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases [LYOS], Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS], Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA], Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER] |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Survival Population [SDV.CAN]Life Sciences [q-bio]/Cancer Diseases of the musculoskeletal system Periostin Serum biomarker [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract 03 medical and health sciences 0302 clinical medicine [SDV.CAN] Life Sciences [q-bio]/Cancer Internal medicine [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN] medicine Lung cancer education Prospective cohort study RC254-282 Survival analysis education.field_of_study [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system business.industry bone metastasis periostin lung cancer serum biomarker survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens Bone metastasis medicine.disease 3. Good health 030104 developmental biology RC925-935 [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system 030220 oncology & carcinogenesis Adenocarcinoma Biomarker (medicine) [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN] business Research Paper |
| Zdroj: | Journal of Bone Oncology Journal of Bone Oncology, 2021, 29, pp.100364. ⟨10.1016/j.jbo.2021.100364⟩ Journal of Bone Oncology, Amsterdam : Elsevier, c2012-, 2021, 29, pp.100364. ⟨10.1016/j.jbo.2021.100364⟩ Journal of Bone Oncology, Vol 29, Iss, Pp 100364-(2021) |
| ISSN: | 2212-1374 2212-1366 |
| DOI: | 10.1016/j.jbo.2021.100364⟩ |
| Popis: | International audience; More than 35% of lung adenocarcinoma patients have bone metastases at diagnosis and have a poor survival. Periostin, a carboxylated matrix protein, mediates lung cancer cell dissemination by promoting epithelial-mesenchymal transition, and is involved in bone response to mechanical stress and bone formation regulation. This suggests that periostin may be used as a biomarker to predict survival in lung cancer patients.Serum periostin was assessed at diagnosis in a prospective cohort of 133 patients with lung adenocarcinoma of all stages. Patients were divided into localized and bone metastatic groups. Both groups were matched to healthy controls. Survival analysis and Cox proportional hazards models were conducted in the total population and in bone metastatic group.The median serum periostin level was higher in bone metastatic (n = 67; median: 1752 pmol/L) than in the localized group (n = 66; 861 pmol/L; p median) had a poorer overall survival in the whole population (33.3 weeks vs. NR; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|